Pathways Study: Puberty Suppression Debate
Full Debate: Read Full DebateJonathan Davies
Main Page: Jonathan Davies (Labour - Mid Derbyshire)Department Debates - View all Jonathan Davies's debates with the Department of Health and Social Care
(1 month, 1 week ago)
Commons ChamberThe hon. Lady is right to draw attention to some of the gateways that children and young people will have to go through before being accepted on to the trial. That will involve not just the child assenting and the parents giving consent, but the NHS care team and a national multidisciplinary team, which will take into consideration all the different aspects of a child’s life that I set out in my earlier remarks about their health, but also the wider context that the children are coming from. The importance here is to ensure that there is an exceptionally high bar for children and young people taking part in this trial, and that is the process that has now been established.
Jonathan Davies (Mid Derbyshire) (Lab)
I thank the Secretary of State for the considered way in which he has delivered his statement. In December 2025, The BMJ reported that
“the Pathways trial should wait for findings from former patients treated by GIDS between 2009 and 2020”
and that
“A data linkage study of 9000 patients, now adults, has full HRA approval, and NHS England has encouraged gender clinicians to cooperate, describing it as an opportunity to gather ‘high quality evidence.’”
But The BMJ reported that the clinicians
“refused to share their data”.
Hilary Cass said that was “extraordinary”. Can he tell us whether all the data that is out there is available and whether it is being shared appropriately?
My hon. Friend asks about the data linkage study, and I apologise to my hon. Friend the Member for North Northumberland (David Smith), who a few seconds ago also asked about that—I did not respond then but can now address both questions together.
It is important to understand that the information in the linkage study is much more limited than the detailed information that the research team will be able to collect about the relative benefits and risks of puberty blockers. NHS England is, however, committed to delivering the data linkage study. NHS England, since assuming responsibility for that study, has taken time to ensure that the data is shared by relevant organisations. Let me be absolutely clear, for the avoidance of all doubt, that the Government’s clear expectation is that all relevant organisations will provide the data required to complete the study.